The development of a coronavirus vaccine has brought the Mainz biotechnology company Biontech a solid increase in sales: For the past year, the Mainz biotechnology company expects sales of 482.3 million euros – after only around 108.6 million euros in the previous year. The bottom line was a profit of 15 million euros.
Biontech boss Ugur Sahin spoke of a “transformative year” for his company and was optimistic: “We are already seeing the first signs that the number of Covid-19 cases and mortality in several countries in connection with vaccination are falling” . The proceeds from the sale of the Covid-19 vaccines will be invested in the development of new vaccines and drugs. The good business figures caused the share price of Biontech to rise sharply.
So far, Biontech has delivered more than 200 million Covid-19 vaccine doses. Orders for 1.4 million cans are on the books for 2021. Biontech and its partner Pfizer want to produce around 500 million doses more vaccine than previously planned. Biontech is now assuming a production capacity of up to 2.5 billion vaccine doses, the company announced.
The two partners had recently raised their production target to 2.3 to 2.4 from the previous two billion cans. “The increase was mainly made possible by improved manufacturing processes, the commissioning of Biontech’s production facility in Marburg, the approval of the withdrawal of a sixth vaccine dose and the expansion of our manufacturer and supplier network,” the company explained. Biontech is holding further discussions with potential partners.